Venlafaxine

Indications & formulation #

Major depressive disorder in adults. This reference covers the selected formulation; other indications and products need their own evidence.

Dose reference #

Adult educational reference · Oral extended-release tablet · United States. The clinician selects treatment after assessment; this page does not calculate or change a prescription.

Usually 75 mg/day with food; some patients start 37.5 mg/day for 4–7 days. Selected outpatient reference maximum: 225 mg/day; reassess before increases.

Contraindications & important cautions #

Avoid MAOIs; check blood pressure and serotonergic combinations. Withdrawal may be prominent.

Selected important cautions; consult the full product information for all contraindications and warnings.

Adverse effects #

Nausea, sweating, sexual effects, blood-pressure changes and discontinuation symptoms are relevant.

Interactions #

Review serotonergic combinations, MAO inhibitors and factors affecting the parent drug and active metabolite.

Monitoring #

Monitor blood pressure, function, activation and tolerability; renal/hepatic context and release formulation affect prescribing.

Special populations #

Renal and hepatic impairment require reductions; the degree depends on severity and dialysis. Use the specific label adjustment table.

Adult scope. Pregnancy, breastfeeding and pediatric use require the exact product’s population-specific guidance and individual assessment.

Discontinuation, restarting & counseling #

Individualize gradual dose reduction; some patients need a prolonged taper.

Brands & products #

Reference coverage #

Structured summary of selected adult uses, not an exhaustive monograph. Indian product authorization and local prescribing requirements have not been reconciled.